Searchable abstracts of presentations at key conferences in endocrinology

ea0063p743 | Thyroid 2 | ECE2019

The prevalence of anti-parietal cell and tissue-transglutaminase antibodies in patients with autoimmune thyroid disease: a preliminary report

Rosenblum Rachel Chava , Rotman-Pikielny Pnina , Shapiro Menachem , Twito Orit

Background: The association between autoimmune thyroid disease (AITD) and other autoimmune diseases is well-known. The prevalence of concurrent autoimmune gastritis and celiac disease in AITD has been estimated at approximately 20–25% and 2–5% respectively. Although both conditions have significant morbidity including malignancy and may necessitate dietary modifications and endoscopic evaluation, no recommendation exists to screen AITD patients for these autoimmune d...

ea0063p50 | Adrenal and Neuroendocrine Tumours 1 | ECE2019

A seminoma with entrapped nerve ganglion masquerading as a paraganglioma

Rosenblum Rachel Chava , Atlan Karine , Diment Judith , Mazeh Haggi , Rotman-Pikielny Pnina , Twito Orit

Background: The differential diagnosis of retroperitoneal tumors includes lymphoid, germ cell and neurogenic tumors such as paraganglioma. Paragangliomas are rare neuroendocrine tumors of the autonomic nervous system, which may secrete catecholamines and their metabolites. Clinical features include sustained or paroxysmal hypertension, headaches, sweating and palpitations. Here we present an unusual case of a retroperitoneal tumor entrapping a sympathetic nerve ganglion and mi...

ea0063p107 | Calcium and Bone 1 | ECE2019

Pseudohypoparathyroidism- a tale of hypo- and hypercalcemia with a genetic solution

Chava Rosenblum Rachel , Einbinder Yael , Twito Orit , Mantovani Giovanna , Marta Elli Francesca , Rotman-Pikielny Pnina

Introduction: Pseudohypoparathyroidism (PHP) is a rare genetic disease characterized by renal resistance to parathyroid hormone (PTH), presenting with hypocalcemia, hyperphosphatemia and elevated PTH levels. We describe a PHP patient who presented with clinically significant hypercalcemia.Case description: A 46-year-old woman with a prior history of hypocalcemia presented to the emergency department with new-onset hypercalcemia, renal failure and anemia....

ea0070ep71 | Bone and Calcium | ECE2020

Efficacy and safety of pamidronate in the treatment of parathyroid hormone-dependent hypercalcemia in hospitalized patients

Chava Rosenblum Rachel , Twito Orit , Barzilay-Yoseph Liat , Ramaty Erez , Klein Noa , Rotman-Pikielny Pnina

Background: Bisphosphonates are effective in malignancy-related hypercalcemia and have been beneficial in parathyroid-hormone (PTH)-dependent hypercalcemia in small randomized-controlled trials. However, data regarding efficacy and safety in PTH-dependent hypercalcemia is limited, and pamidronate is not indicated for this condition.Objective: To evaluate efficacy and safety of pamidronate in moderate-severe PTH-dependent hypercalcemia. Control groups wer...

ea0073aep135 | Calcium and Bone | ECE2021

Osteoporosis treatment following osteoporotic fractures- data from a single medical center

Tell-Lebanon Osnat , Rosenblum Rachel Hava , Yaccobi Eyal , Ohana Nissim , Twito Orit , Rotman-Pikielny Pnina

BackgroundMost post-osteoporotic fracture patients do not receive osteoporosis treatment, although it reduces risks for additional fractures. This retrospective, observational study reviewed osteoporosis evaluation and treatment following typical osteoporotic fractures.MethodsWe identified patients with hip, vertebral, humerus or radius fractures, examined in Meir Medical Center, January-December 2017. Exclus...

ea0090p299 | Calcium and Bone | ECE2023

Parathyroid hormone levels following denosumab therapy vs. zoledronic acid therapy for osteoporosis

Rotman Pikielny Pnina , Hornik Lurie Tzipi , Barzilai-Yosef Liat , Ramaty Erez , Braginski Shapira Sofia , Kasher Miron Michal

Background: Denosumab (DMAb) and zoledronic acid (ZA) are potent, anti-resorptive agents used to treat patients with osteoporosis. It has been suggested that they increase parathyroid hormone (PTH) levels in response to their antiresorptive effect, and that PTH elevation might be responsible for DMAb modeling actions on bone. The timeline and magnitude of PTH elevation post-DMAb and ZA has not been characterized in a large patient population.Objective: T...